NVS
January 31, 2024 - AI Summary
Overvalued by 3% based on the discounted cash flow analysis.
Market cap | $213.17 Billion |
---|---|
Enterprise Value | $230.76 Billion |
Dividend Yield | $3.7395 (3.84%) |
Earnings per Share | $7.34 |
Beta | 0.36 |
Outstanding Shares | 2,189,930,497 |
Avg 30 Day Volume | 1,939,249 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 13.98 |
---|---|
PEG | 81.17 |
Price to Sales | 4.87 |
Price to Book Ratio | 5.41 |
Enterprise Value to Revenue | 5.06 |
Enterprise Value to EBIT | 21.79 |
Enterprise Value to Net Income | 15 |
Total Debt to Enterprise | 0.12 |
Debt to Equity | 0.69 |
No data
No data
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segm...